AXL and melanoma: Indeed, AXL+/WNT5A+ melanoma cells are resistant to MAPK pathway inhibitors (Konieczkowski et al., 2014; Muller et al., 2014) and this might, at least in part, be due to the fact that the regulation of MITF expression is disconnected from BRAF.